ZymoGenetics(美國)

ZymoGenetics

美國ZymoGeneticswww.zymogenetics.comZymoGenetics總部設(shè)在西雅圖市，其開發(fā)的藥物包括人造血管凝乳酶Recothrom，主要用于手術(shù)時防止失血過多。2010年百時美施貴寶8.85億美元收購ZymoGenetics Foundedin1981,ZymoGeneticsisabiopharmaceuticalcompanywithadevelopmentpipe lineofproteins,antibodies,andantibody-likemolecules.ZymoGeneticsispubliclytraded(NASDAQ:ZGEN)andheadquarteredinSeattle,WashingtoninthehistoricSeattleCityLightSteamPlantbuilding.Ourmissionistocreatenovelproteindrugsthatwillsignificantlyhelppatientsfighttheirdiseases.Wehavecontributedtothediscoveryordevelopmentofsixrecombinantproteinproductsnowmarketedbyothercompanies.Currentprogramstargetinflammatoryandautoimmunediseases,bleeding,cancerandviralindications.Ourfirstinternallydevelopedproduct,RECOTHROM®Thrombin,topical(Recombinant),wasapprovedbytheU.S.FoodandDrugAdministration(FDA)onJanuary17,2008foruseasatopicalhemostatto